France European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both the US and China every year; recent data from ING shows that the percentage of global new drug approvals originating…
France Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path for others to follow. Amolyt Pharma When AstraZeneca’s rare diseases arm Alexion acquired Lyon-based Amolyt Pharma in a deal…
See our Cookie Privacy Policy Here
